Literature DB >> 14574616

Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

J Macías1, J A Pineda, F Lozano, J E Corzo, A Ramos, E León, J A García-García, J Fernández-Rivera, J A Mira, J Gómez-Mateos.   

Abstract

Coinfection with the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) is highly prevalent in southern Europe. However, there are few and contradictory data about the effect of HCV carriage on the response to highly active antiretroviral therapy (HAART). In this study, the recovery of CD4+ T cells following HAART among antiretroviral-naïve patients seropositive for HIV with and without HCV coinfection was investigated. Two hundred one HIV-infected patients without previous exposure to antiretroviral drugs were included in the study. HCV coinfection was detected in 123 (61%) patients. The time to recover 200 CD4+ cells/ microl was longer in the HCV-positive group ( P<0.001). In a Cox model, HCV infection and lack of persistent HIV viremia (defined as <200 copies/ml) were associated with the time to recover 200 CD4+ cells/ microl. The mean increase in CD4+ cell counts was lower in the HCV-positive group during the first year of therapy. HIV/HCV-coinfected patients naïve for antiretroviral therapy show a delayed recovery of CD4+ cell counts after starting HAART.

Entities:  

Mesh:

Year:  2003        PMID: 14574616     DOI: 10.1007/s10096-003-1015-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

Review 1.  Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

Authors:  Vincent Soriano; Mark Sulkowski; Colm Bergin; Angelos Hatzakis; Patrice Cacoub; Christine Katlama; Antonietta Cargnel; Stefan Mauss; Douglas Dieterich; Santiago Moreno; Carlo Ferrari; Thierry Poynard; Jürgen Rockstroh
Journal:  AIDS       Date:  2002-04-12       Impact factor: 4.177

2.  Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C.

Authors:  N Taya; Y Torimoto; M Shindo; K Hirai; C Hasebe; Y Kohgo
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

3.  Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

Authors:  G M Lucas; L W Cheever; R E Chaisson; R D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

4.  Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity.

Authors:  E Toubi; A Kessel; L Goldstein; G Slobodin; E Sabo; Z Shmuel; E Zuckerman
Journal:  J Hepatol       Date:  2001-12       Impact factor: 25.083

5.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

6.  CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients.

Authors:  J M Franco; J A León-Leal; M Leal; A Cano-Rodriguez; J A Pineda; J Macías; A Rubio; C Rey; B Sanchez; E Lissen
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1.

Authors:  T Laskus; M Radkowski; L F Wang; H Vargas; J Rakela
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

9.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

10.  No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Authors:  Zabrina L Brumme; Keith J Chan; Winnie W Dong; Theresa Mo; Brian Wynhoven; Robert S Hogg; Julio S Montaner; Michael V O'Shaughnessy; P Richard Harrigan
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

View more
  14 in total

1.  Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors.

Authors:  Mohammad M Sajadi; Roopa Pulijala; Robert R Redfield; Rohit Talwani
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

2.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

3.  Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Authors:  Sandra Olukemi Ogwu-Richard; David Ajiboye Ojo; Olusola Abiodun Akingbade; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

Review 4.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

5.  Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection.

Authors:  Angel M Mayor; Maria A Gomez; Diana M Fernandez; Eddy Rios-Olivares; James C Thomas; Robert F Hunter
Journal:  Am J Trop Med Hyg       Date:  2006-02       Impact factor: 2.345

6.  Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment.

Authors:  G F de Larrañaga; S D A Perés Wingeyer; L M Puga; B S Alonso; J A Benetucci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

7.  Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women.

Authors:  Jerome Kerzerho; Elizabeth J McIlvaine; Patricia Anthony; Wendy J Mack; Chia-Hao Wang; Toni Frederick; Eva Operskalski; Zhi Chen; Lena Al-Harthi; Alan Landay; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Omid Akbari; Elizabeth T Golub; Gerald B Sharp; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

8.  Impact of hepatitis C on survival of HIV-infected individuals in Shiraz; South of Iran.

Authors:  Abbas Rezaianzadeh; Jafar Hasanzadeh; Abbas Alipour; Mohamed Ali Davarpanah; Abdorreza Rajaeifard; Seyed Hamid Reza Tabatabaee
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

9.  Effects of HCV on basal and tat-induced HIV LTR activation.

Authors:  Satarupa Sengupta; Eleanor Powell; Ling Kong; Jason T Blackard
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.

Authors:  M Santin; M Mestre; E Shaw; M J Barbera; A Casanova; J Niubo; F Bolao; D Podzamczer; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.